In a research report published Thursday, Needham analyst Alan Carr downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold, following the company’s fourth-quarter financial results, which were …
In a research report published Monday, JP Morgan analyst Cory Kasimov maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) with a price target …
In a research note sent to investors today, J.P.
